Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks

Clinical trial NCT01772134 · COMPLETED

Trial details

NCT number: NCT01772134
Sponsor: GlaxoSmithKline
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Pulmonary Disease, Chronic Obstructive

Start date: 2013-01-01
Primary completion: 2013-07-01
Enrollment: 617

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.